MCE 的所有產(chǎn)品僅用作科學研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務。

PX-478

產(chǎn)品活性：PX-478 是一種具有口服活性的 HIF-1α 抑制劑，并具有抗癌活性。PX-478 可穿透血腦屏障。

研究領域：Metabolic Enzyme/Protease  |  Autophagy

作用靶點：HIF/HIF Prolyl-Hydroxylase  |  Autophagy

In Vitro: PC3 and DU 145 cells express HIF-1α protein are treated with PX-478 for 20 hr under normoxia. PC3 cells are more sensitive to PX-478 as compared with DU 145 cells. Densitometric analysis shows that the IC₅₀ for HIF-1α inhibition for PC3 cells under normoxic condition is 20-25 μM, whereas the IC₅₀ for HIF-1α inhibition for the DU 145 cells is 40-50 μM. PC3 and DU 145 cells are treated with different concentrations of PX-478 (10, 20, 30, 40, 50, and 60 μM) for 18-20 hr under normoxia or hypoxia. Under normoxia, PC3 cells are more sensitive to PX-478 than DU 145 cells. IC₅₀ for clonogenic survival (n=3) is 17 μM for PC3 cells and 35 μM for DU 145 cells. When cells are treated with the drug under hypoxic condition for 18 hr, the IC₅₀ is 16 μM for PC3 cells and 22 μM for DU 145 cells. Thus DU 145 cells are more sensitive to PX-478 under hypoxic condition.

In Vivo: PX-478 is administered to mice with congenital HO (Nfatc1-Cre/caACVR1^fl/fl) every other day starting from birth for 2 wk. Treated mice have significantly less ectopic bone at the ankle joints compared with mutant mice treated with vehicle (6.8 mm³ vs. 2.2 mm³, P<0.01).

相關產(chǎn)品：Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  HIF-2α-IN-8  |  Glucosamine sulfate  |  HIF1-IN-3  |  Threo-Chloramphenicol-d₆  |  Amifostine trihydrate  |  Albendazole  |  AKBA  |  Deferoxamine  |  LW6  |  PT2399  |  Dimethyl-bisphenol A  |  Ethyl 3,4-dihydroxybenzoate  |  Roxadustat  |  KG-548  |  Daprodustat  |  1,4-DPCA ethyl ester  |  AKB-6899  |  7-Hydroxyneolamellarin A  |  Glucosamine-¹³C₆,¹⁵N (hydrochloride)  |  BAY 87-2243  |  β,β-Dimethylacrylshikonin  |  PT-2385  |  Adaptaquin  |  (Rac)-Arnebin 1  |  Echinomycin  |  AFP464 free base  |  HIF-PHD-IN-1  |  1,4-DPCA

品牌介紹:
•   MCE (MedChemExpress) 擁有200 多種全球僅有化合物庫，我們致力于為全球科研客戶提供前沿的高品質(zhì)小分子活性化合物；
•   50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領；
•   產(chǎn)品種類涵蓋各種重組蛋白，多肽，常用試劑盒 ，更有 PROTAC、ADC 等特色產(chǎn)品，廣泛應用于新藥研發(fā)、生命科學等科研項目；
•   提供虛擬篩選，離子通道篩選，代謝組學分析檢測分析，藥物篩選等專業(yè)技術(shù)服務；
•   設有專業(yè)的實驗中心和嚴格的質(zhì)控、驗證體系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質(zhì)檢報告，確保產(chǎn)品的高純度、高品質(zhì)；
•   產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證；
•   Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果；
•   專業(yè)團隊跟蹤最新的制藥及生命科學研究進展，為您提供全球新的活性化合物；
•   與世界各大制藥公司及著名科研機構(gòu)建立了長期的合作。